[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Kruse
H P
HP
Abt. für Nephrologie u. Osteologie, Univ.-Klinikum Hamburg-Eppendorf. h.kruse@uke.uni-hamburg.de
D000368:Aged; D019386:Alendronate / Q000008:administration & dosage / Q000191:economics; D003362:Cost-Benefit Analysis; D012968:Etidronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D005260:Female; D005598:Fractures, Spontaneous / Q000191:economics* / Q000517:prevention & control; D005858:Germany; D006801:Humans; D009313:National Health Programs / Q000191:economics*; D015663:Osteoporosis, Postmenopausal / Q000191:economics* / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage / Q000191:economics; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000191:economics / Q000517:prevention & control
D020849:Raloxifene Hydrochloride; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate